Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort
- Palacios-Baena, Zaira Raquel
- Gutiérrez-Gutiérrez, Belén
- Calbo, Esther
- Almirante, Benito
- Viale, Pierluigi
- Oliver, Antonio
- Pintado, Vicente
- Gasch, Oriol
- Martínez-Martínez, Luis
- Pitout, Johann
- Akova, Murat
- Peña, Carmen
- Molina Gil-Bermejo, José
- Hernández, Alicia
- Venditti, Mario
- Prim, Nuria
- Bou, German
- Tacconelli, Evelina
- Tumbarello, Mario
- Hamprecht, Axel
- Giamarellou, Helen
- Almela, Manel
- Pérez, Federico
- Schwaber, Mitchell J
- Bermejo, Joaquín
- Lowman, Warren
- Hsueh, Po-Ren
- Paño-Pardo, José Ramón
- Torre-Cisneros, Julián
- Souli, Maria
- Bonomo, Robert A
- Carmeli, Yehuda
- Paterson, David L
- Pascual, Álvaro
- Rodríguez-Baño, Jesús
- Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group
DOIAbstract
There is little information about the efficacy of active alternative drugs to carbapenems except β-lactam/β-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems
Add to ORKG